TSS
OCRX

Two Sigma Securities’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Two Sigma Securities’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-19,180
Closed -$25K – 1318
2017
Q1 		$25K Buy
+19,180
New +$24.4K ﹤0.01% 840

Other funds holding OCRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Securities's OCRX Position: Q2 2017 in Review

Two Sigma Securities sold out of Ocera Therapeutics, Inc. (OCRX) in Q2 2017, closing a stake of 19,180 shares — an estimated $25K sold.

Two Sigma Securities first reported a position in OCRX in Q1 2017 and held it in 1 quarter. The position peaked at $25K in Q1 2017. 24 funds tracked by Wall St. Rank hold OCRX as of Q2 2017.

  • Two Sigma Securities reported no remaining Ocera Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Two Sigma Securities sold 19,180 Ocera Therapeutics, Inc. shares in Q2 2017, an estimated $25K.
  • Two Sigma Securities first reported a position in Ocera Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Two Sigma Securities's Ocera Therapeutics, Inc. position peaked at $25K in Q1 2017.
  • 24 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q2 2017.

Based on Two Sigma Securities's 13F filing for Q2 2017, filed 14 Aug 2017.